Nanostructured lipid carriers system: Recent advances in drug delivery

Journal of Drug Targeting

Volumn 20, Issue 10, 2012, Pages 813-830

  Iqbal, Md Asif ^a   Md, Shadab ^a   Sahni, Jasjeet Kaur ^a   Baboota, Sanjula ^a   Dang, Shweta ^b   Ali, Javed ^a  

^a HAMDARD UNIVERSITY   (India)

^b JAYPEE INSTITUTE OF INFORMATION TECHNOLOGY   (India)

Author keywords

colloidal carrier; drug delivery; lipid; Nanostructured lipid carriers; surfactants

Indexed keywords

BENZOCAINE; BETA CAROTENE; CALCIPOTRIOL; CELECOXIB; CLOTRIMAZOLE; CORTICOSTEROID; CYCLODEXTRIN; CYCLOSPORIN; CYPROTERONE ACETATE; DOMPERIDONE; DRUG CARRIER; GLYCEROL BEHENATE; INDOMETACIN; KETOCONAZOLE; KETOPROFEN; LIDOCAINE; METHOTREXATE; MINOXIDIL; NANOSTRUCTURED LIPID CARRIER; NITROSYL RUTHENIUM COMPLEX; OXYBENZONE; PROGESTERONE; PSORALEN; RUTHENIUM; TACROLIMUS; TAZAROTENE; THIOCTIC ACID; TOCOL; UBIDECARENONE; UNCLASSIFIED DRUG; VINPOCETINE;

ATOPIC DERMATITIS; AUTONOMIC NEUROPATHY; CARDIAC AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; DIABETIC NEUROPATHY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG PENETRATION; ERYTHEMA; HUMAN; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; INTRAOCULAR DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PARTICLE SIZE; POSTOPERATIVE PAIN; POSTTRAUMATIC PAIN; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN ALLERGY; SKIN BURNING SENSATION; SKIN CANCER; SKIN DISEASE; SKIN STINGING; TOPICAL DRUG ADMINISTRATION; ZETA POTENTIAL;

COLLOIDS; CRYSTALLIZATION; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; LIPIDS; NANOSTRUCTURES;

EID: 84868353989     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.716845     Document Type: Review

References (114)

1. Anton N, Benoit JP, Saulnier P. (2008). Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release, 128, 185-199.
2. Benson HA, Sarveiya V, Risk S, Roberts MS. (2005). Influence of anatomical site and topical formulation on skin penetration of sunscreens. Ther Clin Risk Manag, 1, 209-218.
3. Bilska A, Wlodek L. (2005). Lipoic acid-the drug of the future? Pharmacol Rep, 57, 570-577.
4. Bunjes H, Westsen K, Koch MHJ. (1996). Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm 129, 159-173. (Pubitemid 26098737)
5. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. (2002). Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm, 238, 241-245. (Pubitemid 34457892)
6. Chen CC, Tsai TH, Huang ZR, Fang JY. (2010). Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm, 74, 474-482.
7. Chan J, Maghraby GM, Craig JP, Alany RG. (2007). Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. Int J Pharm, 328, 65-71. (Pubitemid 44827562)
8. Charcosset C, El-Harati A, Fessi H. (2005). Preparation of solid lipid nanoparticles using a membrane contactor. J Control Release, 108, 112-120. (Pubitemid 41476679)
9. Charman WN. (2000). Lipids, lipophilic drugs, and oral drug deliverysome emerging concepts. J Pharm Sci, 89, 967-978.
10. Charman WN, Porter CJ, Mithani S, Dressman JB. (1997). Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci, 86, 269-282. (Pubitemid 27113759)
11. Cirri M, Bragagni M, Mennini N, Mura P. (2012). Development of a new delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for ketoprofen topical delivery. Eur J Pharm Biopharm, 80, 46-53.
12. Cook N, Freeman S. (2001). Report of 19 cases of photoallergic contact dermatitis to sunscreens seen at the Skin and Cancer Foundation. Australas J Dermatol, 42, 257-259. (Pubitemid 34007633)
13. Covino BG, Vassallo HG. (1976). Local anesthetics: mechanisms of action and clinical use. 1st ed. (Grune & Stratton: New York) 123-148.
14. Das S, Chaudhury A. (2011). Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech, 12, 62-76.
15. Davidson MH, Lukacsko P, Sun JX, Phillips G, Walters E, Sterman A, Niecestro R, Friedhoff L. (2002). A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended-and immediate-release formulations of lovastatin. Clin Ther, 24, 112-125. (Pubitemid 34117528)
16. Doktorovová S, Araújo J, Garcia ML, Rakovský E, Souto EB. (2010). Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). Colloids Surf B Biointerfaces, 75, 538-542.
17. Eitenmiller RR, Landen Jr, WO. (1998). Vitamin analysis for the health and food sciences (Woodhead Publishing: Cambridge, UK).
18. Estella-Hermoso de Mendoza A, Campanero MA, Mollinedo F, Blanco-Prieto MJ. (2009). Lipid nanomedicines for anticancer drug therapy. J Biomed Nanotechnol, 5, 323-543.
19. Fang JY, Fang CL, Liu CH, Su YH. (2008). Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm, 70, 633-640.
20. Foye WO, Lemke TL, Williams DA. (2007). Foye's principles of medicinal chemistry, 6th ed. (Philadelphia, PA: Lippincott Williams & Wilkins).
21. Freitas C, Muller RH. (1998). Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN (TM)) dispersions. Int J Pharm, 168, 221-229. (Pubitemid 28349963)
22. Gasco MR. (1993). Method for producing solid lipid microspheres having a narrow size distribution US Patent 5 250 236.
23. Gavini E, Chetoni P, Cossu M, Alvarez MG, Saettone MF, Giunchedi P. (2004). PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies. Eur J Pharm Biopharm, 57, 207-212. (Pubitemid 38283696)
24. Gill PS, Espina BM, Muggia F, Cabriales S, Tulpule A, Esplin JA, Liebman HA, Forssen E, Ross ME, Levine AM. (1995). Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol, 13, 996-1003.
25. Gonzalez-Miraa E, Egeaa MA, Garciaa M, Souto EB. (2010). Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf B Biointerfaces, 81, 412-421.
26. Hagedorn-Leweke U, Lippold BC. (1998). Accumulation of sunscreens and other compounds in keratinous substrates. Eur J Pharm Biopharm, 46, 215-221. (Pubitemid 28414481)
27. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. (2002). A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res, 19, 875-880. (Pubitemid 34692585)
28. Huang ZR, Hua SC, Yang YL, Fang JY. (2008). Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol Sin, 29, 1094-1102.
29. Hung LC, Basri M, Tejo BA, Ismail R, Nang HL, Abu Hassan H, May CY. (2011). An improved method for the preparations of nanostructured lipid carriers containing heat-sensitive bioactives. Colloids Surf B Biointerfaces, 87, 180-186.
30. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Baner K, Benet LZ, Sewing KF, Christians U. (1999). Small intestinal metabolism of the 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitor lovastatin and comparison with pravastatin. J Pharmacol Exp Ther, 291, 131-139. (Pubitemid 29451582)
31. Jain NK, Ram A. (2011). Development and characterization of nanostructured lipid carriers of oral hypoglycemic agent selection of surfactants. Int J Pharm Sci Rev Res 7, 125-130.
32. Jaques PA, Kim CS. (2000). Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women. Inhal Toxicol, 12, 715-731.
33. Jia L, Zhang D, Li Z, Duan C, Wang Y, Feng F, Wang F, Liu Y, Zhang Q. (2010). Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies. Colloids Surf B Biointerfaces, 80, 213-218.
34. Joshi M, Patravale V. (2008). Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm, 346, 124-132. (Pubitemid 350110507)
35. Kakkar V, Singh S, Singla D, Kaur IP. (2011). Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res, 55, 495-503.
36. Köhn FM, Schill WB. (2003). A new oral testosterone undecanoate formulation. World J Urol, 21, 311-315.
37. Kumar VV, Chandrasekar D, Ramakrishna S, Kishan V, Rao YM, Diwan PV. (2007). Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm, 335, 167-175. (Pubitemid 46482862)
38. Lauweryns JM, Baert JH. (1977). Alveolar clearance and the role of the pulmonary lymphatics. Am Rev Respir Dis, 115, 625-683. (Pubitemid 8074576)
39. Leonard M. (1998). Carl Koller: mankind's greatest benefactor? The story of local anesthesia. J Dent Res, 77, 535-538. (Pubitemid 32774139)
40. Li N, Zhuang C, Wang M, Sun X, Nie S, Pan W. (2009). Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm, 379, 131-138.
41. Liedtke S, Zimmermann E, Muller RH, Mader K. (1999). Physical characterisation of solid lipid nanoparticles (SLN). Proc Int Symp Control Release Bioact Mater, 26, 595-596.
42. Lin YK, Huang ZR, Zhuo RZ, Fang JY. (2010). Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int J Nanomedicine, 5, 117-128.
43. Lipinski C. (2002). Poor aqueous solubility: an industry wide problem in drug discovery. Am Pharm Rev 5, 82-85.
44. Liu CH, Wu CT. (2010). Optimization of nanostructured lipid carriers for lutein delivery. Colloids Surf B Biointerfaces, 353, 149-156.
45. Liu DH, Liu CX, Zou WW, Zhang N. (2010). Enhanced gastrointestinal absorption of N-3-O-toluyl-fluorouracil by cationic solid lipid nanoparticles. J Nanopart Res, 12, 975-984.
46. Liu D, Liu Z, Wang L, Zhang C, Zhang N. (2011). Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces, 85, 262-269.
47. Madishetti SK, Palem CR, Gannu R, Thatipamula RP, Panakanti PK, Yamsani MR. (2010). Development of domperidone bilayered matrix type transdermal patches: physicochemical, in vitro and ex vivo characterization. Daru, 18, 221-229.
48. Marquele-Oliveiraa F, de Almeida Santanaa DC, Taveiraa SF, Vermeulena DM, de Oliveirab ARM, da Silva RS, Lopeza RFV. (2010). Development of nitrosyl ruthenium complex-loaded lipid carriers for topical administration: improvement in skin stability and in nitric oxide release by visible light irradiation. J Pharm Biomed Anal, 53, 843-851.
49. Mehnert W, Mäder K. (2001). Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev, 47, 165-196. (Pubitemid 32324113)
50. Muchow M, Maincent P, Müller RH, Keck CM. (2011). Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement. Drug Dev Ind Pharm, 37, 8-14.
51. Muller RH, Dingler A. (1998). The next generation after the liposomes: solid lipid nano particles (SLN®, LipopearlsTM) as dermal carrier in cosmetics. Eurocosmetics. 8, 19-26.
52. Muller RH, Lucks JS. (1996). Arzneistoffträger aus festen Lipidteilchen-Feste Lipid Nanosphären (SLN). European Patent 0605497.
53. Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm, 50, 161-177. (Pubitemid 30326695)
54. Müller RH, Petersen RD, Hommoss A, Pardeike J. (2007). Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev, 59, 522-530. (Pubitemid 47271894)
55. Müller RH, Radtke M, Wissing SA. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev, 54 Suppl 1, S131-S155. (Pubitemid 35379959)
56. Müller RH, Radtke M, Wissing SA. (2002). Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm, 242, 121-128.
57. Müller RH, Radtke M, Wissing SA. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev, 54 Suppl 1, S131-S155. (Pubitemid 35379959)
58. Müller RH, Runge SA, Ravelli V, Thünemann AF, Mehnert W, Souto EB. (2008). Cyclosporine-loaded solid lipid nanoparticles (SLN): druglipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm, 68, 535-544. (Pubitemid 351318197)
59. Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB. (2006). Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm, 317, 82-89. (Pubitemid 43866342)
60. Müller RH, Shegokar R, Keck CM. (2011). 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol, 8, 207-227.
61. Nakai Y, Yamamoto K, Terada K, Akimoto K. (1984). The dispersed states of medicinal molecules in ground mixtures with α-or β-cyclodextrin. Chem Pharm Bull, 32, 685-690.
62. Obeidat WM, Schwabe K, Müller RH, Keck CM. (2010). Preservation of nanostructured lipid carriers (NLC). Eur J Pharm Biopharm, 76, 56-67.
63. Ogretmen B, Safa AR. (1999). Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with the CAAT region. Biochemistry, 38, 2189-2199.
64. Packer L. (1998). alpha-Lipoic acid: a metabolic antioxidant which regulates NF-kappa B signal transduction and protects against oxidative injury. Drug Metab Rev, 30, 245-275. (Pubitemid 28266862)
65. Paliwal R, Rai S, Vaidya B, Khatri K, Goyal AK, Mishra N, Mehta A, Vyas SP. (2009). Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine, 5, 184-191.
66. Pandey R, Khuller GK. (2005). Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb), 85, 227-234. (Pubitemid 40805619)
67. Pardeike J, Hommoss A, Müller RH. (2009). Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm, 366, 170-184.
68. Pardeike J, Weber S, Haber T, Wagner J, Zarfl HP, Plank H, Zimmer A. (2011). Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int J Pharm, 419, 329-338.
69. Patel M, Jain SK, Yadav AK, Gogna D, Agrawal GP. (2006). Preparation and characterization of oxybenzone-loaded gelatin microspheres for enhancement of sunscreening efficacy. Drug Deliv, 13, 323-330. (Pubitemid 44180012)
70. Pathak P, Nagarsenker M. (2009). Formulation and evaluation of lidocaine lipid nanosystems for dermal delivery. AAPS PharmSciTech, 10, 985-992.
71. Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PN, Singh M. (2010). Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release, 144, 233-241.
72. Pople PV, Singh KK. (2011). Development and evaluation of colloidal modified nanolipid carrier: application to topical delivery of tacrolimus. Eur J Pharm Biopharm, 79, 82-94.
73. Puglia C, Sarpietro MG, Bonina F, Castelli F, Zammataro M, Chiechio S. (2011). Development, characterization, and in vitro and in vivo evaluation of benzocaine-and lidocaine-loaded nanostructrured lipid carriers. J Pharm Sci, 100, 1892-1899.
74. Radomska-Soukharev A. (2007). Stability of lipid excipients in solid lipid nanoparticles. Adv Drug Deliv Rev, 59, 411-418. (Pubitemid 47259223)
75. Radtke M. (2001). Pure drug nanoparticles for the formulation of poorly soluble drugs. New Drugs 3, 62-68.
76. Ricci M, Puglia C, Bonina F, Di Giovanni C, Giovagnoli S, Rossi C. (2005). Evaluation of indomethacin percutaneous absorption from nanostructured lipid carriers (NLC): in vitro and in vivo studies. J Pharm Sci, 94, 1149-1159. (Pubitemid 40780779)
77. Ruktanonchai U, Bejrapha P, Sakulkhu U, Opanasopit P, Bunyapraphatsara N, Junyaprasert V, Puttipipatkhachorn S. (2009). Physiochemical Characteristics, cytotoxicity, and antioxidant activity of three lipid nanoparticulate formulations of alpha-lipoic Acid. AAPS PharmSciTech, 10, 227-234.
78. Ruktanonchai U, Bejrapha P, Sakulkhu U, Opanasopit P, Bunyapraphatsara N, Junyaprasert V, Puttipipatkhachorn S. (2009). Physicochemical characteristics, cytotoxicity, and antioxidant activity of three lipid nanoparticulate formulations of alpha-lipoic acid. AAPS PharmSciTech, 10, 227-234.
79. Sahana B, Santra K, Basu S, Mukherjee B. (2010). Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in-vitro evaluation. Int J Nanomedicine, 5, 621-630.
80. Sanad RA, Abdelmalak NS, Elbayoomy TS, Badawi AA. (2010). Formulation of a novel oxybenzone-loaded nanostructured lipid carriers (NLCs). AAPS PharmSciTech, 11, 1684-1694.
81. Sanjula B, Shah FM, Javed A, Alka A. (2009). Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J Drug Target, 17, 249-256.
82. Schubert MA, Müller-Goymann CC. (2003). Solvent injection as a new approach for manufacturing lipid nanoparticles-evaluation of the method and process parameters. Eur J Pharm Biopharm, 55, 125-131. (Pubitemid 36120504)
83. Shahgaldian P, Da Silva E, Coleman AW, Rather B, Zaworotko MJ. (2003). Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters. Int J Pharm, 253, 23-38. (Pubitemid 36197828)
84. Shidhaye SS, Vaidya R, Sutar S, Patwardhan A, Kadam VJ. (2008). Solid lipid nanoparticles and nanostructured lipid carriers-innovative generations of solid lipid carriers. Curr Drug Deliv, 5, 324-331.
85. Silva AC, Santos D, Ferreira DC, Souto EB. (2009). Minoxidil-loaded nanostructured lipid carriers (NLC): characterization and rheological behaviour of topical formulations. Pharmazie, 64, 177-182.
86. Sjöström B, Bergenståhl B. (1992). Preparation of submicron drug particles in lecithin-stabilized o/w emulsions I. Model studies of the precipitation of cholesteryl acetate. Int J Pharm 88, 53-62. (Pubitemid 23000408)
87. Smith DW, Peterson MR, DeBerard SC. (1999). Local anesthesia. Topical application, local infiltration, and field block. Postgrad Med, 106, 57-60, 64.
88. Souto EB. (2005). SLN and NLC for Topical Delivery of Antifungals. Ph.D. Thesis. Institute of Pharmacy, Free University of Berlin, Germany.
89. Souto EB, Müller RH. (2006). The use of SLN and NLC as topical particulate carriers for imidazole antifungal agents. Pharmazie, 61, 431-437. (Pubitemid 43724420)
90. Souto EB, Muller RH. (2007). Nanoparticulate drug delivery systems.Thassu D, Deleers M, Pathak Y (eds) vol. 166 (New York, London: Informa Healthcare) 213-233.
91. Souto EB, Almeida AJ, Muller RH. (2007). Lipid Nanoparticles (SLN®, NLC®) for cutaneous drug delivery: structure, protection and skin effects. J Biomed Nanotechnol, 3, 317-331. (Pubitemid 351877135)
92. Souto EB, Mehnert W, Müller RH. (2006). Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC. J Microencapsul, 23, 417-433. (Pubitemid 44132550)
93. Souto EB, Wissing SA, Barbosa CM, Müller RH. (2004). Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm, 278, 71-77. (Pubitemid 38670438)
94. Souza LG, Silva EJ, Martins AL, Mota MF, Braga RC, Lima EM, Valadares MC, Taveira SF, Marreto RN. (2011). Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur J Pharm Biopharm, 79, 189-196.
95. Stecová J, Mehnert W, Blaschke T, Kleuser B, Sivaramakrishnan R, Zouboulis CC, Seltmann H, Korting HC, Kramer KD, Schäfer-Korting M. (2007). Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm Res, 24, 991-1000. (Pubitemid 46675401)
96. Sweetman SC. (2007). Matrindale the complete drug reference (Pharmaceutucal press London, UK) 1556-1557.
97. Teeranachaideekul V, Müller RH, Junyaprasert VB. (2007). Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)-effects of formulation parameters on physicochemical stability. Int J Pharm, 340, 198-206. (Pubitemid 47049784)
98. Teeranachaideekul V, Souto EB, Junyaprasert VB, Müller RH. (2007). Cetyl palmitate-based NLC for topical delivery of Coenzyme Q(10)-development, physicochemical characterization and in vitro release studies. Eur J Pharm Biopharm, 67, 141-148. (Pubitemid 46991336)
99. Thatipamula R, Palem C, Gannu R, Mudragada S, Yamsani M. (2011). Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. Daru, 19, 23-32.
100. Trotta M, Debernardi F, Caputo O. (2003). Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm, 257, 153-160. (Pubitemid 36507041)
101. Tsai MJ, Huang YB, Wu PC, Fu YS, Kao YR, Fang JY, Tsai YH. (2011). Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci, 100, 547-557.
102. Uner M, Yener G. (2007). Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine, 2, 289-300. (Pubitemid 350047774)
103. Wollin SD, Jones PJ. (2003). Alpha-lipoic acid and cardiovascular disease. J Nutr, 133, 3327-3330.
104. Xie S, Pan B, Wang M, Zhu L, Wang F, Dong Z, Wang X, Zhou W. (2010). Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles. Nanomedicine (Lond), 5, 693-701.
105. Yamamoto T, Nishioka K. (2003). Topical tacrolimus: an effective therapy for facial psoriasis. Eur J Dermatol, 13, 471-473. (Pubitemid 37305092)
106. Yuan H, Wang LL, Du YZ, You J, Hu FQ, Zeng S. (2007). Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf B Biointerfaces, 60, 174-179. (Pubitemid 350030429)
107. Zauner W, Farrow NA, Haines AM. (2001). In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density. J Control Release, 71, 39-51. (Pubitemid 32195440)
108. Zhai H, Maibach HI. (2001). Effects of skin occlusion on percutaneous absorption: an overview. Skin Pharmacol Appl Skin Physiol, 14, 1-10. (Pubitemid 32098521)
109. Zhang J, Fan Y, Smith E. (2009). Experimental design for the optimization of lipid nanoparticles. J Pharm Sci, 98, 1813-1819.
110. Zhuang CY, Li N, Wang M, Zhang XN, Pan WS, Peng JJ, Pan YS, Tang X. (2010). Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm, 394, 179-185.
111. Ziegler D, Gries FA. (1997). Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes, 46 Suppl 2, S62-S66. (Pubitemid 27377401)
112. Zimmermann E, Liedtke S, Muller RH, Mader K. 1999. H-NMR as a method to characterize colloidal carrier systems. Proc Int Symp Control Release Bioact Mater 26, 591-592.
113. zur Mühlen A, Schwarz C, Mehnert W. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm, 45, 149-155. (Pubitemid 28167741)
114. zur Mühlen A, zur Mühlen E, Niehus H, Mehnert W. (1996). Atomic force microscopy studies of solid lipid nanoparticles. Pharm Res, 13, 1411-1416. (Pubitemid 26344991)